India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

LONDON, UK I June 12, 2025 I GSK plc (LSE/NYSE: GSK) announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Bharat Biotech partners with GSK to lead Phase 3 trials and manufacturing of altSonflex1-2-3, targeting deadly Shigella ...

Bharat Biotech and GSK collaborate to advance Shigella vaccine, aiming to combat urgent public health threat globally.

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...